Teva expands blood pressure drug recall in the US amid cancer fearsTeva has expanded a recall of losartan potassium tablets after tests revealed a potential human carcinogen in the Share XTeva expands blood pressure drug recall in the US amid cancer fearshttps://pharmaphorum.com/news/teva-expands-blood-pressure-drug-recall-in-the-us-amid-cancer-fears/
Teva settles Oklahoma opioid lawsuit ahead of trialTeva has opted to settle the first trial among hundreds of cases that accuse it and other drugmakers Share XTeva settles Oklahoma opioid lawsuit ahead of trialhttps://pharmaphorum.com/news/teva-settles-oklahoma-opioid-lawsuit-ahead-of-trial/
Teva vows to fight price-fixing lawsuitTeva has said it will defend itself against a lawsuit raised by 44 US states that alleges the Share XTeva vows to fight price-fixing lawsuithttps://pharmaphorum.com/news/teva-vows-to-fight-price-fixing-lawsuit/
Novartis sues as Amgen tries to cancel migraine tie-upNovartis and Amgen have become embroiled in a legal row over rights to the migraine prevention drug Aimovig, Share XNovartis sues as Amgen tries to cancel migraine tie-uphttps://pharmaphorum.com/news/novartis-sues-as-amgen-tries-to-cancel-migraine-tie-up/
Teva’s migraine drug Ajovy approved in EuropeTeva’s migraine drug Ajovy (fremanezumab) has been approved in Europe, taking on rivals from the same class from Share XTeva’s migraine drug Ajovy approved in Europehttps://pharmaphorum.com/news/tevas-migraine-drug-ajovy-approved-in-europe/
Novo prevents Teva’s Victoza rival launch until 2023Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a Share XNovo prevents Teva’s Victoza rival launch until 2023https://pharmaphorum.com/news/novo-prevents-tevas-victoza-rival-launch-until-2023/
Q4 results roundup 2019With the full year results season drawing to a close, Richard Staines asks who the winners were and Share XQ4 results roundup 2019https://pharmaphorum.com/sales-marketing/q4-results-roundup-2019/
Teva’s migraine drug Ajovy looks set for EU approvalTeva’s migraine drug Ajovy (fremanezumab) has moved closer to the EU market after the influential CHMP regulatory committee Share XTeva’s migraine drug Ajovy looks set for EU approvalhttps://pharmaphorum.com/news/tevas-migraine-drug-ajovy-looks-set-for-eu-approval/
CVS covers migraine drugs from Teva and Lilly, excludes Amgen’s rivalUS pharmacy benefits manager CVS Health Corp has added new migraine drugs from Teva and Eli Lilly to Share XCVS covers migraine drugs from Teva and Lilly, excludes Amgen’s rivalhttps://pharmaphorum.com/news/cvs-covers-migraine-drugs-from-teva-and-lilly-excludes-amgens-rival/
